Every year, over 60 million abdominal surgeries are performed worldwide. 1 of 5 patients will likely develop an incisional hernia within 5 years, a complication linked to chronic pain, repeated surgeries, and over 5% mortality.
A major cause for this complication is the premature degradation of standard sutures like PDS-II, which lose tensile strength after just 8 weeks, while most patients require support for at least 24 weeks.
PPCA® is a platform-level breakthrough in absorbable polymer science, designed to enable a new class of effective, cost-neutral surgical products for the global market.
PPCA® polymer technology is a novel class of biodegradable tri-block polymer developed at the Hebrew University, representing a material science breakthrough in surgical wound management.
Voyager Medical’s PPCA® polymer supports a wide range of surgical applications
From sutures and hernia repair to breast reconstruction and urogenital health. The following sections outline its key clinical uses and advantages.
Voyager Medical Research is a next-gen medical device company founded on the belief that innovation must serve both clinical outcomes and cost-efficiency. At the heart of our mission is a groundbreaking bioresorbable polymer platform, PPCA®, designed to meet critical unmet needs in surgery without raising the economic burden on health systems.
The company was founded by Ohad Lavi, Prof. Daniel Cohn, and Prof. Ariel Halevy a multidisciplinary leadership team with unmatched depth in surgical care, polymer science, and healthcare commercialization.
